Status:

RECRUITING

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

Lead Sponsor:

University Hospital, Grenoble

Conditions:

Breast Cancer Metastatic

Eligibility:

FEMALE

18-99 years

Phase:

PHASE3

Brief Summary

DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, op...

Detailed Description

In women, breast cancer is the 1st largest cancer and accounted for 31% of new cancer cases in women in 2017. With 11,913 deaths in 2015, breast cancer is the 1st largest cancer death in women (19%) a...

Eligibility Criteria

Inclusion

  • Age over 18
  • Patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer
  • Patient labeled on the primary lesion ER+HER2- (20)
  • Presence of metastatic liver and bone lesions identifiable with 18F-FDG PET-Scan
  • Presence of at least 10 identifiable secondary lesions in 18F-FDG PET-Scan
  • No therapeutic change between 18F-FDG PET-Scan and 68Ga-DOTATOC PET-Scan.
  • Performing the PET scan with 68Ga-DOTATOC within a maximum of 21 days after the 18F-FDG PET-Scan
  • Person affiliated to or benefiting from social security
  • Person who has given written informed consent

Exclusion

  • Patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor)
  • Known allergy to 68Ga-DOTATOC or its excipients
  • Subject refusing to sign the consent to participate
  • Minor subject
  • Subject excluded from another study
  • Persons referred to Articles L1121-5 to L1121-8 of the Public Health Code (CSP)
  • Subject cannot be contacted in case of emergency

Key Trial Info

Start Date :

January 6 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2026

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT06611891

Start Date

January 6 2025

End Date

October 1 2026

Last Update

March 4 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU Grenoble Alpes

Grenoble, France, 38043